Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4463-4465

  Leeds, J A ^a   Sachdeva, M ^a   Mullin, S ^a   Dzink Fox, J ^a   LaMarche, M J ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Global Discovery Chemistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ELONGATION FACTOR TU; FIDAXOMICIN; LFF 571; LINEZOLID; METRONIDAZOLE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ANTI-BACTERIAL AGENTS; BINDING SITES; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDE CHAIN ELONGATION, TRANSLATIONAL; PEPTIDE ELONGATION FACTOR TU; PROTEIN STRUCTURE, TERTIARY; THIAZOLES;

EID: 84864386108     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06354-11     Document Type: Article

References (24)

1. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat. Rev. Gastroenterol. Hepatol. 8:17-26.
2. Bauer MP, Kuijper EJ, van Dissel JT. 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15:1067-1079.
3. Reference deleted.
4. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 56:2493-2503.
5. Clinical and Laboratory Standards Institute. 2010. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 7th ed. Approved standard M11-7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S21. Twenty-first informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Critchley IA, et al. 2009. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J. Antimicrob. Chemother. 63:954-963.
8. Crook D, et al. 2010. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs vancomycin, abstr P-LB2401. Abstr. 20th Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria.
9. Deng G, et al. 2011. Investigation of mode of binding of elongation factor tu inhibitor LFF571, abstr F1-1859. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
10. Dzink-Fox J, et al. 2011 Antimicrobial activity of the novel elongation factor Tu Inhibitor, LFF571, abstr F1-1346. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
11. Gerding DN, Muto CA, Owens RC, Jr. 2008. Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl 1):S32-S42. (Pubitemid 351323663)
12. Hecht D, Osmolski J, Gerding D. 2012. Activity of LFF571 against 103 clinical isolates of C. difficile, abstr P1440. Abstr. 22nd Eur. Society of Clinical Microbiology and Infectious Diseases, London, United Kingdom.
13. Karasawa T, Ikoma S, Yamakawa K, Nakamura S. 1995. A defined growth medium for Clostridium difficile. Microbiology 141:371-375.
14. LaMarche MJ, et al. 2012. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J. Med. Chem. 55:2376-2387.
15. Leeds JA, et al. 2011. In vitro and in vivo activities of novel, semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu. Antimicrob. Agents Chemother. 55:5277-5283.
16. Louie TJ, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
17. Miller M, Mullane KM, Weiss K. 2009. OPT-80 versus vancomycin in Clostridium difficile infection: results of randomized clinical trial. Gastroenterology 136(Suppl 1):A-115. doi:10.1016/S0016-5085(09)60516-3.
18. Nelson RL. 18 July 2007. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 2007:CD004610.
19. Parmeggiani A, et al. 2006. Structural basis of the action of pulvomycin and GE2270 A on elongation factor Tu. Biochemistry 45:6846-6857. (Pubitemid 43856670)
20. Perkins HR, Nieto M. 1974. The chemical basis for the action of the vancomycin group of antibiotics. Ann. N. Y. Acad. Sci. 235:348-363.
21. Selva E, et al. 1991. Antibiotic GE2270 a: a novel inhibitor of bacterial protein synthesis. I. Isolation and characterization. J. Antibiot. (Tokyo) 44:693-701.
22. Trzasko A, Leeds JA, Praestgaard J, LaMarche MJ, McKenney D. 2012. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob. Agents Chemother. 56:4459-4462.
23. Viswanathan VK, Mallozzi MJ, Vedantam G. 2010. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 1:234-242.
24. Zuurmond AM, et al. 2000. GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J. Mol. Biol. 304:995-1005.